Solara zooms on getting CEP approval to manufacture Ibuprofen from Vishakhapatnam Facility
Follow us Now on Telegram ! Get daily 10 - 12 important updates on Business, Finance and Investment. Join our Telegram Channel
Solara Active Pharma Sciences is currently trading at Rs. 415.00, up by 17.35 points or 4.36% from its previous closing of Rs. 397.65 on the BSE.
The scrip opened at Rs. 397.40 and has touched a high and low of Rs. 419.65 and Rs. 392.45 respectively. So far 10241 shares were traded on the counter.
The BSE group 'A' stock of face value Rs. 10 has touched a 52 week high of Rs. 1385.00 on 10-Nov-2021 and a 52 week low of Rs. 323.65 on 20-Jun-2022.
Last one week high and low of the scrip stood at Rs. 421.75 and Rs. 392.45 respectively. The current market cap of the company is Rs. 1496.90 crore.
The promoters holding in the company stood at 40.40%, while Institutions and Non-Institutions held 21.44% and 38.16% respectively.
Solara Active Pharma Sciences (Solara) has received ‘Certificate of Suitability’ (CEP) approval for its new state of the art multipurpose API manufacturing facility at Vishakhapatnam, Andhra Pradesh, for the manufacture of Ibuprofen API, from European Directorate for the Quality of Medicines (EDQM), the first international regulatory approval for this new facility.
With this key approval, Solara has CEP approval for two manufacturing facilities for Ibuprofen API, the other being its dedicated manufacturing facility located at Puducherry, India. Solara also expects series of other international regulatory approvals for its Vizag facility, including USFDA.
Solara Active Pharma Sciences is a young, dynamic, entrepreneurial and customer oriented API manufacturer.
